From antipsychotic to anti-schizophrenia drugs: Role of animal models

Trends in Pharmacological Sciences

Volumn 33, Issue 10, 2012, Pages 515-521

  Geyer, Mark A ^a,b   Olivier, Berend ^c   Joëls, Marian ^d   Kahn, René S ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

cognition; dopamine; psychosis; schizophrenia; translational psychiatry

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHLORPROMAZINE; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PLACEBO; VARENICLINE;

BEHAVIORAL RESEARCH; COGNITIVE DEFECT; COGNITIVE THERAPY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; EXPERIMENTAL MODEL; HUMAN; MENTAL HEALTH; NEGATIVE SYNDROME; NONHUMAN; PANIC; PHOBIA; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SMOKING CESSATION; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIPSYCHOTIC AGENTS; DISEASE MODELS, ANIMAL; HUMANS; SCHIZOPHRENIA;

EID: 84866739960     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2012.06.006     Document Type: Review

References (47)

1. T.A. Ban The role of serendipity in drug discovery Dialogues Clin. Neurosci. 8 2006 335 344 (Pubitemid 44682750)
2. H. Laborit Étude expérimentale du syndrome d'irritation et application clinique à la maladie post-traumatique Thérapie 4 1949 126 139 (in French)
3. H. Laborit Un nouveau stabilisateur végétative (le 4560 RP) Presse Méd. 60 1952 37 348
4. P. Seeman, and T. Lee Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons Science 188 1975 1217 1219
5. S. Leucht Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis Lancet 373 2009 31 41
6. M. Davidson Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST) Am. J. Psychiatry 166 2009 675 682
7. J. Kane Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine Arch. Gen. Psychiatry 45 1988 789 796
8. 2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient Biol. Psychiatry 50 2001 873 883 (Pubitemid 34020700)
9. S.T. Patil Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial Nat. Med. 13 2007 1102 1107 (Pubitemid 47517511)
10. J.W. Young Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia Pharmacol. Ther. 122 2009 150 202
11. J.R. Field Targeting glutamate synapses in schizophrenia Trends Mol. Med. 17 2011 689 698
12. M.J. Kas Translational neuroscience of schizophrenia: seeking a meeting of minds between mouse and man Sci. Transl. Med. 3 2011 102mr3
13. J.D. Hegarty One hundred years of schizophrenia: a meta-analysis of the outcome literature Am. J. Psychiatry 151 1994 1409 1416 (Pubitemid 24301683)
14. M.J. Owen Suggestion of roles for both common and rare risk variants in genome-wide studies of schizophrenia Arch. Gen. Psychiatry 67 2010 667 673
15. A. Reichenberg Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study Am. J. Psychiatry 167 2010 160 169
16. C.J. van Oel School performance as a premorbid marker for schizophrenia: a twin study Schizophr. Bull. 28 2002 401 414 (Pubitemid 36193860)
17. D.J. Done Childhood antecedents of schizophrenia and affective illness: a social adjustment at ages 7 and 11 Br. Med. J. 309 1994 699 703 (Pubitemid 24285221)
18. P.J. Harrison, and D.R. Weinberger Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence Mol. Psychiatry 10 2005 40 68 (Pubitemid 40139588)
19. H.E. Hulshoff Pol, and R.S. Kahn What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia Schizophr. Bull. 34 2008 354 366 (Pubitemid 351323347)
20. N.E. van Haren Changes in cortical thickness during the course of illness in schizophrenia Arch. Gen. Psychiatry 68 2011 871 880
21. A. Markou Removing obstacles in neuroscience drug discovery: the future path for animal models Neuropsychopharmacol. Rev. 34 2009 74 89
22. M.A. Geyer Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review Psychopharmacology 156 2001 117 154 (Pubitemid 32702206)
23. J.E. Henningfield, and S.R. Goldberg Control of behavior by intravenous nicotine injections in human subjects Pharmacol. Biochem. Behav. 19 1983 1021 1026 (Pubitemid 14209528)
24. 2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid Neuropharmacology 52 2007 985 994 (Pubitemid 46227486)
25. M.R. Picciotto Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine Nature 391 1998 173 177 (Pubitemid 28092475)
26. U. Maskos Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors Nature 436 2005 103 107 (Pubitemid 40966193)
27. 2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats Psychopharmacology 208 2010 365 376
28. 2 nACh receptors for smoking cessation Trends Pharmacol. Sci. 28 2007 316 325 (Pubitemid 47016686)
29. K.M. Myers Glutamate receptors in extinction and extinction-based therapies for psychiatric illness Neuropsychopharmacology 36 2011 274 293
30. D.L. Walker Facilitation of conditioned fear extinction by systemic administration of D-cycloserine as assessed with fear-potentiated startle in rats J. Neurosci. 22 2002 2343 2351 (Pubitemid 35386533)
31. M. Davis Effects of D-cycloserine on extinction: translation from preclinical to clinical work Biol. Psychiatry 60 2006 369 375 (Pubitemid 44215855)
32. D.C. Choi Pharmacological enhancement of behavioral therapy: focus on posttraumatic stress disorder Curr. Top. Behav. Neurosci. 2 2009 279 299
33. K.J. Ressler Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear Arch. Gen. Psychiatry 61 2004 1136 1144 (Pubitemid 39463415)
34. M.M. Norberg A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy Biol. Psychiatry 63 2008 1118 1126
35. M.A. Geyer, and A. Markou Animal models of psychiatric disorders F.E. Bloom, D. Kupfer, Psychopharmacology: Fourth Generation of Progress 1995 Raven Press 787 798
36. S.B. Powell Models of neurodevelopmental abnormalities in schizophrenia Curr. Top. Behav. Neurosci. 4 2010 435 483
37. C.G. AhnAllen The role of the α7 nicotinic receptor in cognitive processing of persons with schizophrenia Curr. Opin. Psychiatry 25 2012 103 108
38. D. Alberati Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia Neuropharmacology 62 2012 1152 1161
39. M.A. Geyer New opportunities in the treatment of cognitive impairments associated with schizophrenia Curr. Dir. Psychol. Sci. 19 2010 264 269
40. S. Floresco Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia Schizophr. Bull. 31 2005 888 894 (Pubitemid 41437783)
41. E. Kraepelin Ein kurzes Lehrbuch für Studirende und Aerzte 4th edn 1893 Verlag von Ambr. Abel 435 445 (in German)
42. E. Bleuler Dementia Praecox, oder die Gruppe der Schizophrenien 1911 Franz Deuticke (in German)
43. M.E. Bouton Contextual and temporal modulation of extinction: behavioral and biological mechanisms Biol. Psychiatry 60 2006 352 360 (Pubitemid 44215847)
44. K.M. Myers, and M. Davis Mechanisms of fear extinction Mol. Psychiatry 12 2007 120 150 (Pubitemid 46160979)
45. J.P. Johansen Molecular mechanisms of fear learning and memory Cell 147 2011 509 524
46. M.R. Milad, and G.J. Quirk Fear extinction as a model for translational neuroscience: ten years of progress Annu. Rev. Psychol. 63 2012 129 151
47. E.A. Phelps, and J.E. LeDoux Contributions of the amygdala to emotion processing: from animal models to human behavior Neuron 48 2005 175 187 (Pubitemid 41476352)